Q-omics provides the consensus-scored RNF145 profile across patient tissues and cancer cell-line models. RNF145 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RNF145 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RNF145 RNA expression shows 20,030 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, KIRC, and KIRP as cancer lineages where RNF145 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF145 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF145 survival associations across molecular data types. RNF145 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF145 RNA expression–survival associations across cancer types. High RNF145 expression shows unfavorable associations in UVM, KICH, LIHC and STAD, but favorable associations in KIRC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RNF145 RNA expression.
This table summarizes RNF145 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RNF145. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF145 shows lower tumor expression in LUSC and BRCA and higher tumor expression in KIRC, KIRP, HNSC and LIHC. The KIRC box plot shows higher RNF145 RNA expression in tumor versus normal tissue (log2 FC = +1.281, t-test p < 0.001).
This table shows molecular features associated with RNF145 in patient tissues and cancer cell lines. In patient samples, RNF145 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF145 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
